NASDAQ NMS - GLOBAL MARKET · BIIB

-0.20% · -$0.3900

Biogen Inc

Biotechnology

$196.00

+ Add to watchlist

Veridion Score

BETAHIGH CONF · 5/6 factors

As of May 31, 9:48 PM EDT · BIIB

Methodology

64/100

BUY BIAS

Composite intelligence score across six weighted factors. Higher score = stronger composite signal.

Score history: Coverage building

Institutional Flow · 90D

Corporate Insiders

SEC Form 4

60/ 100

+1K net shares (90d) · 3B / 2S

US Congress

Senate eFD + House STOCK Act

—/ 100

no data

Wall Street Analysts

Sell-side consensus

69/ 100

9 SB · 15 B · 18 H · 1 S

Sovereign · $25/mo

See why this score moved.

· Factor breakdown with raw signals
· Day-over-day delta + driver
· Factor coverage readout
· Insider · Congress · Wall Street flow
· Pro Chart event markers
· Score history + alerts

Start Sovereign · $25/mo →

Cancel anytime · or Reserve · $79/mo

Confidence: HIGH · 5/6 factors with data · Computed May 31, 9:48 PM EDT · Refreshes hourly

Share on X →

Veridion Score History · 90D

Composite trend over time

LOADING HISTORY…

REFRESHES DAILY

AI Analysis

BETA

Why is BIIB moving today?

Analyzing news articles + insider activity + analyst signals…

About Biogen Inc

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Founded

—

Listed

1991

Employees

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Company website →

Open

$195.55

Previous close

$196.39

Day high

$198.46

Day low

$195.11

Market cap

$28.94B

IPO

1991-09-17

Country

Currency

USD

Data ledger

Quote and day range

As of May 29, 4:00 PM EDT

Source: Market data

Veridion Score

As of May 31, 9:48 PM EDT

Source: Veridion methodology

Chart and risk context

Daily bars with no missing-bar fill

Source: Market data

News and filings

Refresh intervals shown inside each panel

Source: Market news and federal filings

Financials

Loading quarterly statements…

Insider activity · 6M

Loading Form 4 filings…

Congress · 90D

Loading PTR filings…

Federal contracts

BIIB contract awards, year to date.

Public federal awards linked to this ticker.

—

Refresh interval: 12hSource: Federal contract awards

No federal contracts on file for BIIB in this window.

Lobbying spend

BIIB lobbying filings, year to date.

Registered lobbying filings matched to Biogen Inc.

$2.4M

Refresh interval: 12hSource: LDA disclosure filings

Health Issues Medical/Disease Research/Clinical Labs Taxation/Internal Revenue Code Trade (domestic/foreign) Pharmacy Copyright/Patent/TrademarkHealth Issues Medicare/MedicaidMedicare/Medicaid Health Issues Pharmacy Taxation/Internal Revenue Code Trade (domestic/foreign)

Filing

$1.5M

BIOGEN

Apr 20, 2026

Filing

$770.0K

BIOGEN

Jan 19, 2026

Filing

$60.0K

BIOGEN INC.

DLA PIPER LLP (US)